Brand’s technological innovation and broad capabilities are making ideas into reality across Europe’s key sectors

MUNICH and TAIPEI, Oct. 22, 2024 /PRNewswire/ — SINBON, a Taiwan-based electronic interconnect design and integration service provider, is unveiling its latest solutions to be showcased at the upcoming Electronica 2024 trade show. The lineup illustrates how the brand’s robust technological innovation and broad customization capabilities are expanding possibilities for Europe’s most critical industries.

Please join SINBON at Hall A2, Booth 241 at Electronica 2024: Messe München, Nov. 12 – 15, 2024

For visitors to experience firsthand, SINBON will have over 60 products for various industries on display, including several solutions new to Electronica this year:

Industrial IoT: Hybrid SPE connectors—the topic of a SINBON webinar to be broadcast live at the booth—and customized solutions for smart factories, robotics, and warehouse systemsGreen energy: Customized solutions for solar energy infrastructureElectric vehicle and e-mobility: NACS AC/DC charging cables; swappable batteries; customized connectors; CCS1 and CCS2 DC charging cables and inlets; connectors tailored to e-scooters and e-motorcycles; and system integration for e-bikesMedical: Solutions for patient monitoring equipment and surgical instruments; and the Electrical Muscle Stimulation (EMS) Impulse Pack with Arm Straps

Transforming the impossible to the possible across industries: VIRALIETY

SINBON’s theme for Electronica this year will be “VIRALIETY: Unreal to Real”— coined by combining the limitless possibilities of “virtual reality” with “variety.” The theme reflects the company’s ability to innovate to overcome challenges for customers with novel solutions, as well as its extensive capabilities and reach across industries.

“SINBON keeps some of Europe’s biggest industries linked with the latest connector technologies,” noted Barrie Ryan, President of SINBON Europe. “We’ve achieved this reach by transforming our clients’ ideas into reality. Often a solution doesn’t exist yet, and we have the capabilities to turn the impossible into the possible across a wide variety of sectors.” 

Exploring how hybrid SPE accelerates industrial IoT

Hybrid single pair ethernet (SPE) delivers greater power and data transmission speeds while minimizing cables in industrial spaces. To explore this new connectivity technology, SINBON’s booth will feature a live broadcast of the company’s webinar Elevating Industrial Connectivity: Hybrid Single Pair Ethernet on Thursday, November 14, 2024, 10:30AM Central European Summer Time (UTC +02:00).

Webinar details and registration: https://us02web.zoom.us/webinar/register/WN_B2c6tSpSQw24W4-kBO6Hyg#/registration

Interactive, hands-on experiences at Electronica 2024

Offering a new and memorable way to interact with SINBON experts, visitors to the booth will have the chance to play a game that involves finding the SINBON guru using Augmented Reality. Participants will be able to win a unique gift from the company.

Booth visitors will also have the chance to test SINBON’s solutions for themselves. For industrial and automotive industries, the company is making its charging cables for robots and EVs available for attendees to experience how quickly and seamlessly they charge. In addition, visitors can also try out the new EMS Arm Straps. Lastly, SINBON will share numerous product stories that explore how they came to life and how they solve customer pain points.

About SINBON Electronics

Established in 1989 in Taiwan, SINBON Electronics is a leading provider of integrated design and production services for bespoke interconnect solutions. Driven by a commitment to customer centricity and the principles of ESG, the company offers a wide range of products and OEM/ODM services that ensure reliability and efficiency, combining extensive engineering expertise, industry knowledge, and leading innovations to customize solutions for long-term customer success. SINBON has a global footprint, with operations in Taiwan, China, Japan, the United Kingdom, Germany, Hungary, and the United States.

To learn more about SINBON’s services, please visit www.sinbon.com or follow on LinkedIn.

Photo – https://mma.prnewswire.com/media/2534417/LinkedIn_1920x1080.jpg
Logo – https://mma.prnewswire.com/media/2533173/SINBON_Electronics_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/sinbon-is-expanding-possibilities-across-industries-at-electronica-2024-302280542.html

225Ac-Satoreotide is a first-in-class somatostatin receptor 2 antagonist targeting extensive stage small cell lung cancer and is the first antagonist labelled with 225Ac to enter clinical developmentSatoreotide expressed a superior pharmacokinetic profile relative to DOTA-TATE with a higher pre-clinical anti-tumour efficacy, irrespective of radionuclide used100% survival with a single dose of 30 kBq 225Ac-satoreotide but not with 225Ac-DOTA-TATE

BERLIN, Oct. 22, 2024 /PRNewswire/ — Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces that it presented data on its proprietary radiolabelled peptide SS0110 (satoreotide), a first-in-class antagonist of the somatostatin receptor 2 (SSTR2), at this year’s European Association of Nuclear Medicine (EANM) Annual Conference, held in Hamburg, Germany from 19-23 October 2024.

The Top-Rated Oral Presentation (TROP) entitled ‘225Ac-SSO110 induces long-lasting anti-tumour responses in contrast to 225Ac-DOTA-TATE and 161Tb-DOTA-TATE in the treatment of SSTR2-positive tumour xenografts’, details the anti-tumour efficacy of different radiolabelled satoreotide antagonists (225Ac, 161Tb, 177Lu-labelled SSO110) versus respective DOTA-TATE agonists (225Ac- and 161Tb-labelled DOTA-TATE) in mice engrafted with SSTR2 positive xenografts of small cell lung cancer (SCLC) and pancreatic cancer using clinically relevant associated dose ranges.  

Results demonstrate that 225Ac-satoreotide shows the strongest anti-tumoural effect in vivo at a low single dose when evaluating satoreotide and DOTA-TATE radiolabelled with different radionuclides. Irrespective of the radionuclides used, satoreotide demonstrated a higher pre-clinical anti-tumour efficacy when compared to DOTA-TATE which was less potent and required increased dose levels. Satoreotide was well tolerated across all dose levels and with all used radionuclides. These comparisons between satoreotide and DOTA-TATE will facilitate and guide further clinical development of satoreotide across multiple indications expressing SSTR2, such as SCLC, pancreatic cancers and Merkel Cell Carcinoma (MCC).

Previous comparisons between satoreotide and DOTA-TATE demonstrated that antagonist, 225Ac-satoreotide, is multiple times more potent than SSTR2 agonist, 225Ac-DOTA-TATE, signifying a durable complete response in standard murine xenograft models of SCLC in animal models, versus tumour growth delay.

Ariceum had previously shown at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 that 212Pb was not seen to be more potent than Lutetium or Terbium but caused more side effects and hence was not further pursued.

Manfred Rüdiger, Chief Executive Officer at Ariceum Therapeutics, said: “These results provide strong evidence for satoreotide and its potential to clinically outperform SSTR2 targeting agonists, by demonstrating significantly better efficacy in tumour growth control, up to complete tumour eradication depending on isotope used. In addition, when a single dose of 30 kBq 225Ac-satoreotide was administered, we observed high frequency of complete durable responses and 100% survival which strongly supports further clinical development for the treatment of SCLC, MCC and other cancers.”

Details of the oral presentation are as follow:

Title: 225Ac-SSO110 induces long-lasting anti-tumour responses in contrast to 225Ac-DOTA-TATE and 161Tb-DOTA-TATE in the treatment of SSTR2-positive tumour xenografts

Presenting Author: Prachi Desai, Scientist at Ariceum Therapeutics

Session Number: 1204
Session Title: M2M Track – TROP Session: Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: From Radionuclide to Clinical Translation

Oral Presentation Date & Time: Tuesday 22 October 2024, 09:00 AM – 09:10 AM CEST

Abstract Authors: Prachi Desai, Manuel Sturzbecher
–  Hoehne,
Dennis Mewis, Manfred Ruediger & Anika Jaekel  of Ariceum Therapeutics

Abstracts are available in the September edition of Springer’s European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) abstract book here and on the Ariceum website here.

About Ariceum Therapeutics

Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium have been huge contributions to finding treatments for cancer.

Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (“Satoreotide”), is an antagonist of the somatostatin type 2 (SSTR2) receptor which is overexpressed in neuroendocrine tumours (NETs) and some aggressive cancers such as small cell lung cancer (SCLC), or Merkel Cell Carcinoma (MCC), all of which have few treatment options and poor prognosis. Satoreotide is being developed as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of these tumours. Ariceum is also developing a radiolabelled PARP-inhibitor (ATT001), currently in Phase 1 clinical development under the trial name CITADEL-123. ATT001 was part of the acquisition of Theragnostics Ltd which was closed in June 2023.

Ariceum Therapeutics, launched in 2021, acquired all rights to Satoreotide from Ipsen. Ipsen remains a shareholder in the Company. Ariceum is headquartered in Berlin, with operations in Germany, Switzerland, Australia, United Kingdom and United States of America and with activities currently across the globe.

Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap, Pureos Bioventures, Andera Partners and Earlybird Venture Capital. For further information, please visit www.ariceum-therapeutics.com.

About European Association of Nuclear Medicine (EANM)

The European Association of Nuclear Medicine (EANM) is a non-profit organization that promotes nuclear medicine and aims to improve public health. The EANM’s mission is to advance nuclear medicine through personalized healthcare, innovation in diagnosis and treatment, and raising awareness of nuclear medicine

View original content:https://www.prnewswire.co.uk/news-releases/ariceum-therapeutics-presents-outstanding-data-on-its-first-in-class-radiopharmaceutical-drug-225ac-satoreotide-at-the-european-association-of-nuclear-medicine-2024-302282011.html

MUMBAI, India, Oct. 22, 2024 /PRNewswire/ — Kotak811 announced the launch of its new YouTube playlist, ‘Scam The Scammers’. This innovative initiative aims to equip customers with the knowledge and tools to protect themselves from financial fraud.

With the surge in digital transactions, financial scams have become increasingly sophisticated. Recognising the need to empower customers, Kotak811 has curated this playlist to serve as a comprehensive resource. The videos cover a wide range of topics, including phishing attacks, fake call scams, and unauthorised transactions, offering viewers a clear understanding of how these scams operate and how to avoid falling victim.

Learn how to scam the scammer

For a deeper understanding of how to stay away from online frauds, explore the dedicated playlist ‘Scam The Scammers’ on YouTube. From detailed explanations to practical tips, these videos offer valuable insights into the safety measures in place.

Watch now: https://www.youtube.com/watch?v=xZreQiJole8&list=PL_M0wBiHI2EMh6X4LfGyXsydBe1wv_nvm&index=4 

About Kotak 811

When 8th November 2016 changed the way India transacted forever, Kotak811 was conceptualized to simplify banking and make it fully accessible online. Kotak811 was launched on 29th March 2017. As one of India’s first full service, truly digital bank, it offers customers a simple and convenient way to open a savings account and transact digitally using 180+ features on its Kotak811 Mobile Banking app, from home or on the move.

On 29th March 2022, Kotak811 presented itself as a bank within a bank, adopting a fresh and new brand identity with ‘digital at its core. As a brand ethos, Kotak811 continuously inquires into India’s banking challenges, innovates to bridge these gaps, and inspires Indians to adopt a way of banking that lets them take full control.

Kotak811 has customers from 1,000+ Cities & Towns covering over 10,000 pin codes, across the country. Every 5 seconds, a new Account is opened digitally. Interestingly, more than 50% of 811 Accounts are opened outside banking hours. Kotak 811 offers instant account opening in 3 mins and KYC via video call in 5 mins.

For more information, please visit the digital bank’s website at https://www.kotak811.com/zero-balance-savings-account-online/

Download the Kotak811 mobile banking app now:

●  For Android users: Mobile Banking App

●  For iOS users: Kotak811 Mobile Banking App

Disclaimer: This Article is for information purpose only

View original content:https://www.prnewswire.com/in/news-releases/kotak811-launches-scam-the-scammers-playlist-to-empower-customers-302282839.html